Abvc Biopharma (ABVC) Receivables - Other (2017 - 2026)

Abvc Biopharma (ABVC) has reported Receivables - Other for 10 consecutive years, with $36184.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other fell 97.46% year-over-year to $36184.0; the trailing twelve-month figure through Jun 2026 stood at $36184.0 (down 97.46% YoY), and the FY2025 full-year result was $763388.0, changed N/A from the prior year.
• Receivables - Other eased to $36184.0 in Q2 2026 per ABVC's latest filing, from $167324.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $1.4 million in Q2 2024 and bottomed at $546.0 in Q3 2025.
• Historically, Receivables - Other has averaged $524927.2 across 5 years, with a median of $523100.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Receivables - Other surged 269.99% in 2023, then plunged 99.95% in 2025.
• Over 5 years, Receivables - Other stood at $757343.0 in 2022, then slumped by 99.65% to $2667.0 in 2023, then soared by 45057.93% to $1.2 million in 2024, then tumbled by 99.81% to $2347.0 in 2025, then soared by 1441.71% to $36184.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $36184.0, $167324.0, and $2347.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.